Table 2. Clinicopathological characteristics of BLCA patients with high/low ACSL4 expression level in TCGA cohort and FUSCC cohort.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Characteristics | TCGA cohort |  |  |  FUSCC cohort |
| High ACSL4 (N=204) | Low ACSL4 (N=204) |  |  |  High ACSL4 (N=15) |  Low ACSL4 (N=15) |  |
| N (%) |  |  |  |  |  |  |
|  Age |  |  |  |  |  |  |
|  ＜70 years | 99(48.5) | 180(88.2) |  |  | 7(46.7) | 10(66.7) |
|  ≥70 years |  105(51.5) | 24(11.8) |  |  | 8(53.3) | 5(33.3) |
|  Gender |  |  |  |  |  |  |
|  Male | 144(72.3) | 157(77.0) |  |  | 9(60.0) | 8(53.3) |
|  Female | 60(27.7) | 47(23.0) |  |  | 6(40.0) | 7(46.7) |
|  Tumor stage  |  |  |  |  |  |  |
|  I-II | 58(40.2) | 74(36.3) |  |  | 13(86.7) | 1(6.7) |
|  III-IV |  144(59.8) | 130(63.7) |  |  | 2(13.3) | 14(93.3) |
| T stage† |  |  |  |  |  |  |
| T1 – T2  | 50(27.8) | 73(37.4) |  |  | 4(36.4) | 3(20.0) |
|  T3 – T4 | 130(72.2) | 122(62.6) |  |  | 11(63.4) | 12(80.0) |
|  N stage† |  |  |  |  |  |  |
|  N0-1 | 102(58.3) | 136(71.0) |  |  | 8(53.3) | 6(40.0) |
| N2-3 | 73(41.7) | 56(18.1) |  |  | 7(46.7) | 9(60.0) |
|  M stage† |  |  |  |  |  |  |
|  M0 | 55(88.7) | 141(97.2) |  |  | 14(93.3) | 12(80.0) |
|  M1 | 7(11.3) | 4(2.7) |  |  | 1(6.7) | 3(20.0) |
| Subtype |  |  |  |  |  |  |
| Papillary | 60(29.6) | 78(52.0) |  |  | 10(66.7) | 9(60.0) |
| Non-Papillary | 143(70.4) | 72(48.0) |  |  | 5(33.3) | 6(40.0) |

† [TNM](https://en.wikipedia.org/wiki/TNM_staging_system) scoring system: Tumor size, Lymph Nodes affected, Metastases.